Clinical and economic evidence supporting a transparent barrier film dressing in XXXX -associated @entity1909 and peri-wound skin protection.

@entity1 @entity322 @entity1947 @entity272 @entity1909
OBJECTIVE: To summarise the clinical and economic literature relating to the effect of Cavilon No Sting Barrier Film on the incidence of @entity322 -associated @entity1909 , which is a risk factor for pressure ulceration and exudate-related peri-wound @entity272 . METHOD: A systematic literature search was performed using available computerised databases for publications on Cavilon barrier film and other relevant terms. Six clinical studies were identified providing data on 1,563 @entity1 treated with the barrier film or a comparator. The publications comprised prospective studies, randomised and non-randomised studies, multicentre trials, single-centre reports and a volunteer study. Due to the nature of the comparators, five studies were open-label. Differences in methodology and outcomes made a qualitative review the most appropriate analysis. RESULTS: The barrier film was at least as effective as petroleum ointments and more effective than @entity1947 formulations in preventing @entity322 -associated @entity1909 . The barrier film was also effective in peri-wound skin protection, although its clinical efficacy was not significantly different to that of petroleum ointments and @entity1947 formulations. Nevertheless, the barrier film was more cost-effective than either petroleum ointments or @entity1947 formulations in managing @entity322 -associated @entity1909 and peri-wound skin protection, largely due to savings in nursing time. CONCLUSION: The barrier film is at least as clinically effective and potentially more cost-effective in @entity322 -associated @entity1909 prophylaxis and peri-wound skin protection than petroleum ointments or @entity1947 formulations, releasing health care resources for alternative use. Further studies are required to quantify the relative efficacy and cost-effectiveness of the barrier film and other barrier formulations in different clinical settings and enhance the quality of the evidence base.
